Anti-inflammatory fibrosis suppression in threatened trabeculectomy bleb failure produces good long term control of intraocular pressure without risk of sight threatening complications
- 1Department of Ophthalmology, University of Otago Medical School, Dunedin, New Zealand
- 2Department of Ophthalmology, Dunedin Hospital, Dunedin, New Zealand
- 3Department of Preventive and Social Medicine, University of Otago Medical School, Dunedin, New Zealand
- Correspondence to: Professor A C B Molteno, Department of Ophthalmology, University of Otago Medical School, PO Box 913, Dunedin, New Zealand; georgi.bond{at}healthotago.co.nz
- Accepted 13 May 2002
Abstract
Aims: To determine the long term outcome of systemic anti-inflammatory fibrosis suppression in cases of threatened trabeculectomy bleb failure in open angle glaucoma.
Methods: This prospective non-comparative case series followed 77 eyes of 63 patients which showed signs of threatened early bleb failure and were treated with oral anti-inflammatory fibrosis suppression of prednisone, a non-steroidal anti-inflammatory agent, and colchicine taken for a mean period of 6 weeks, in addition to standard postoperative topical treatment, for a mean follow up of 6 years.
Results: Trabeculectomy with anti-inflammatory fibrosis suppression controlled the IOP at ≤21 mm Hg with a probability of 0.91 (95% CI: 0.81 to 1.0) at 8 years and 0.89 (95% CI: 0.56 to 1.1) at 12 years. There were no reported cases of endophthalmitis, hypotonous maculopathy, late bleb leak, or serious systemic side effects.
Conclusion: Anti-inflammatory fibrosis suppression provided good control of bleb fibrosis without risk of sight threatening complications in a patient group at high risk of bleb failure.
